HRP20110038T1 - Metoda liječenja dijabetesa tipa-2 - Google Patents
Metoda liječenja dijabetesa tipa-2 Download PDFInfo
- Publication number
- HRP20110038T1 HRP20110038T1 HR20110038T HRP20110038T HRP20110038T1 HR P20110038 T1 HRP20110038 T1 HR P20110038T1 HR 20110038 T HR20110038 T HR 20110038T HR P20110038 T HRP20110038 T HR P20110038T HR P20110038 T1 HRP20110038 T1 HR P20110038T1
- Authority
- HR
- Croatia
- Prior art keywords
- gel composition
- hydroalcoholic gel
- transdermal
- transdermal hydroalcoholic
- testosterone
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract 29
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 22
- 229960003604 testosterone Drugs 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 239000003961 penetration enhancing agent Substances 0.000 claims 3
- 239000002562 thickening agent Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- 239000004584 polyacrylic acid Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000008213 purified water Substances 0.000 claims 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 235000007586 terpenes Nutrition 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66960605P | 2005-04-08 | 2005-04-08 | |
| PCT/EP2006/003974 WO2006108719A1 (en) | 2005-04-08 | 2006-04-07 | Method of treating or preventing type-2 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110038T1 true HRP20110038T1 (hr) | 2011-02-28 |
Family
ID=36609553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110038T HRP20110038T1 (hr) | 2005-04-08 | 2011-01-19 | Metoda liječenja dijabetesa tipa-2 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070088012A1 (pt) |
| EP (1) | EP1865990B1 (pt) |
| JP (1) | JP2008534644A (pt) |
| CN (1) | CN101155598A (pt) |
| AT (1) | ATE486612T1 (pt) |
| AU (1) | AU2006233812B2 (pt) |
| BR (1) | BRPI0610454B8 (pt) |
| CA (1) | CA2604077A1 (pt) |
| DE (1) | DE602006017982D1 (pt) |
| DK (1) | DK1865990T3 (pt) |
| EA (1) | EA013568B1 (pt) |
| ES (1) | ES2354829T3 (pt) |
| HR (1) | HRP20110038T1 (pt) |
| IL (1) | IL186356A (pt) |
| MA (1) | MA29397B1 (pt) |
| MX (1) | MX2007012347A (pt) |
| NO (1) | NO340565B1 (pt) |
| PL (1) | PL1865990T3 (pt) |
| PT (1) | PT1865990E (pt) |
| SI (1) | SI1865990T1 (pt) |
| TN (1) | TNSN07372A1 (pt) |
| UA (1) | UA90307C2 (pt) |
| WO (1) | WO2006108719A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| SI2450041T1 (sl) | 2005-10-12 | 2019-02-28 | Unimed Pharmaceuticals, Llc | Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma |
| PL2219603T3 (pl) * | 2007-11-02 | 2014-10-31 | Acrux Dds Pty Ltd | Układ transdermalnego dostarczania |
| WO2011081915A2 (en) * | 2009-12-15 | 2011-07-07 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| CN114632092B (zh) * | 2022-05-17 | 2022-08-23 | 北京第一生物化学药业有限公司 | 睾丸片在制备具有降糖活性的药物中的应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2155658A (en) * | 1936-01-08 | 1939-04-25 | Chemische Forschungs Gmbh | Surgical and medical preparations |
| US3121042A (en) * | 1959-05-04 | 1964-02-11 | Ercoli Alberto | Oral compositions containing 3-enolethers of methyltestosterone |
| US3164520A (en) * | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| US4009254A (en) * | 1974-05-06 | 1977-02-22 | Colgate-Palmolive Company | Topical compositions |
| US3939111A (en) * | 1974-07-01 | 1976-02-17 | The B. F. Goodrich Company | Stable polyurethane solutions |
| US4197316A (en) * | 1975-07-23 | 1980-04-08 | Scott Eugene J Van | Treatment of dry skin |
| NL7510104A (nl) * | 1975-08-27 | 1977-03-01 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat. |
| US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
| DE2747531A1 (de) * | 1977-10-22 | 1979-04-26 | Basf Ag | Substituierte 3-aminopyrazole |
| US4442094A (en) * | 1980-12-23 | 1984-04-10 | Merck & Co., Inc. | (3-Aralkylamino-2-or-propoxy)heterocyclic compounds |
| US4440777A (en) * | 1981-07-07 | 1984-04-03 | Merck & Co., Inc. | Use of eucalyptol for enhancing skin permeation of bio-affecting agents |
| US4447562A (en) * | 1981-07-15 | 1984-05-08 | Ivani Edward J | Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions |
| US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
| DE3315654A1 (de) * | 1983-04-29 | 1984-10-31 | Bosch Gmbh Robert | Polarographischer messfuehler fuer die bestimmung des sauerstoff-gehaltes in gasen |
| NL8301550A (nl) * | 1983-05-03 | 1984-12-03 | Gist Brocades Nv | Imidazolethanol esters. |
| FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| US4725439A (en) * | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
| US4663157A (en) * | 1985-02-28 | 1987-05-05 | The Proctor & Gamble Company | Sunscreen compositions |
| US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US4820724A (en) * | 1986-03-31 | 1989-04-11 | University Of Southern California | Dual phase solvent carrier system |
| US4981696A (en) * | 1986-12-22 | 1991-01-01 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
| US4906169A (en) * | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US5013553A (en) * | 1987-06-30 | 1991-05-07 | Vipont Pharmaceutical, Inc. | Drug delivery devices |
| US4920203A (en) * | 1987-12-17 | 1990-04-24 | Allied-Signal Inc. | Medical devices fabricated from homopolymers and copolymers having recurring carbonate units |
| US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| ATE230994T1 (de) * | 1989-07-07 | 2003-02-15 | Endorech Inc | Methode zur behandlung androgenbedingter krankheiten |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| JPH04261119A (ja) * | 1991-02-13 | 1992-09-17 | Lintec Corp | 経皮吸収型貼付剤 |
| US5208013A (en) * | 1991-06-03 | 1993-05-04 | Olympus International, Inc. | Composition for skin care and protection |
| US5487898A (en) * | 1991-08-26 | 1996-01-30 | Abbott Laboratories | Compositions and method for the sublingual or buccal administration therapeutic agents |
| JP3202777B2 (ja) * | 1992-01-24 | 2001-08-27 | リンテック株式会社 | 経皮吸収促進剤及びテープ製剤 |
| US5629019A (en) * | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
| TW224048B (pt) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
| US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| WO1994013257A1 (en) * | 1992-12-16 | 1994-06-23 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
| US5881926A (en) * | 1993-03-11 | 1999-03-16 | Taro Pharmaceutical Industries, Ltd. | Pharmaceutical compositions in semisolid form and a device for administration thereof |
| US6010691A (en) * | 1993-03-19 | 2000-01-04 | The Regents Of The University Of California | Methods for enhancing permeation of a topically administered physiologically active substance |
| JP3204510B2 (ja) * | 1993-04-05 | 2001-09-04 | コンペティティブ テクノロジーズ，インク． | 勃起不全の診断および治療 |
| DK0698393T3 (da) * | 1993-05-19 | 2002-08-05 | Hisamitsu Pharmaceutical Co | 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US6024974A (en) * | 1995-01-06 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Composition and methods for transdermal delivery of acid labile drugs |
| US5629021A (en) * | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| AT408067B (de) * | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| US5882676A (en) * | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
| US5902603A (en) * | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
| US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
| DE19619045C1 (de) * | 1996-05-02 | 1997-11-13 | Jenapharm Gmbh | Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen |
| IT1283102B1 (it) * | 1996-06-06 | 1998-04-07 | Permatec Nv | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele |
| US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
| US5708038A (en) * | 1996-06-13 | 1998-01-13 | Univera Pharmaceuticals, Inc. | Method of using aloe vera as a biological vehicle |
| US5863560A (en) * | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
| US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| US6019997A (en) * | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
| GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| US6342250B1 (en) * | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| JP2004515446A (ja) * | 1997-11-24 | 2004-05-27 | ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド | テストステロン阻害剤及びニューロンの保護のためのその用途 |
| US6190693B1 (en) * | 1998-04-17 | 2001-02-20 | Ortho-Mcneil Pharamceutical, Inc. | Pharmaceutical methods of delivering folic acid |
| US6200591B1 (en) * | 1998-06-25 | 2001-03-13 | Anwar A. Hussain | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction |
| US5880117A (en) * | 1998-07-13 | 1999-03-09 | Arnold; Patrick | Use of 4-androstenediol to increase testosterone levels in humans |
| US6207694B1 (en) * | 1998-07-27 | 2001-03-27 | Howard Murad | Pharmaceutical compositions and methods for managing scalp conditions |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| US6187750B1 (en) * | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
| US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| AU3104301A (en) * | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
| CA2405419A1 (en) * | 2000-04-07 | 2001-10-18 | Tap Pharmaceutical Products Inc. | Apomorphine derivatives and methods for their use |
| US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| NZ524601A (en) * | 2000-08-30 | 2006-04-28 | Unimed Pharmaceuticals Inc | Method for treating erectile dysfunction and increasing libido in men |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| JP5039252B2 (ja) * | 2000-08-31 | 2012-10-03 | ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 性機能低下を治療するための医薬組成物及び方法 |
| FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
| DE20121209U1 (de) * | 2000-12-22 | 2002-06-20 | August Wolff Gmbh & Co Arzneim | Gelzusammensetzung zur Behandlung von Hypogonadismus |
| CA2446622C (en) * | 2001-05-11 | 2012-08-14 | Elan Corporation, Plc | Isostearic acid salts as permeation enhancers |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20040072810A1 (en) * | 2001-11-07 | 2004-04-15 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
| AU2003212962A1 (en) * | 2002-02-07 | 2003-09-02 | Massachusetts Institute Of Technology | Transdermal drug delivery systems |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| US6931903B2 (en) * | 2002-06-28 | 2005-08-23 | Gary A. Knudson | Apparatus and method for roll forming shaped members |
| FR2851470B1 (fr) * | 2003-02-20 | 2007-11-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse |
| US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| RU2275930C2 (ru) * | 2004-04-26 | 2006-05-10 | ООО "РусГен" | Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции |
| US20070082039A1 (en) * | 2004-10-18 | 2007-04-12 | Jones Gerald S Jr | Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids |
| AU2006235453A1 (en) * | 2005-04-12 | 2006-10-19 | Laboratories Besins International | Method of treating or preventing bone deterioration or osteoporosis |
| US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
-
2006
- 2006-04-06 US US11/399,642 patent/US20070088012A1/en not_active Abandoned
- 2006-04-07 PT PT06724633T patent/PT1865990E/pt unknown
- 2006-04-07 JP JP2008504713A patent/JP2008534644A/ja active Pending
- 2006-04-07 AT AT06724633T patent/ATE486612T1/de active
- 2006-04-07 DE DE602006017982T patent/DE602006017982D1/de active Active
- 2006-04-07 PL PL06724633T patent/PL1865990T3/pl unknown
- 2006-04-07 WO PCT/EP2006/003974 patent/WO2006108719A1/en active Application Filing
- 2006-04-07 CN CNA2006800114275A patent/CN101155598A/zh active Pending
- 2006-04-07 ES ES06724633T patent/ES2354829T3/es active Active
- 2006-04-07 EA EA200702189A patent/EA013568B1/ru unknown
- 2006-04-07 EP EP06724633A patent/EP1865990B1/en active Active
- 2006-04-07 SI SI200630905T patent/SI1865990T1/sl unknown
- 2006-04-07 DK DK06724633.0T patent/DK1865990T3/da active
- 2006-04-07 AU AU2006233812A patent/AU2006233812B2/en active Active
- 2006-04-07 CA CA002604077A patent/CA2604077A1/en not_active Abandoned
- 2006-04-07 BR BRPI0610454A patent/BRPI0610454B8/pt active IP Right Grant
- 2006-04-07 MX MX2007012347A patent/MX2007012347A/es active IP Right Grant
- 2006-07-04 UA UAA200712429A patent/UA90307C2/uk unknown
-
2007
- 2007-10-05 TN TNP2007000372A patent/TNSN07372A1/en unknown
- 2007-10-07 IL IL186356A patent/IL186356A/en active IP Right Grant
- 2007-10-17 MA MA30305A patent/MA29397B1/fr unknown
- 2007-11-07 NO NO20075695A patent/NO340565B1/no unknown
-
2011
- 2011-01-19 HR HR20110038T patent/HRP20110038T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1865990T1 (sl) | 2011-02-28 |
| EP1865990B1 (en) | 2010-11-03 |
| CA2604077A1 (en) | 2006-10-19 |
| BRPI0610454A2 (pt) | 2010-06-22 |
| EP1865990A1 (en) | 2007-12-19 |
| EA200702189A1 (ru) | 2008-04-28 |
| NO20075695L (no) | 2008-01-07 |
| EA013568B1 (ru) | 2010-06-30 |
| AU2006233812A1 (en) | 2006-10-19 |
| CN101155598A (zh) | 2008-04-02 |
| BRPI0610454B1 (pt) | 2021-05-11 |
| UA90307C2 (uk) | 2010-04-26 |
| IL186356A (en) | 2011-05-31 |
| TNSN07372A1 (en) | 2009-03-17 |
| JP2008534644A (ja) | 2008-08-28 |
| WO2006108719A1 (en) | 2006-10-19 |
| US20070088012A1 (en) | 2007-04-19 |
| DK1865990T3 (da) | 2011-02-14 |
| MA29397B1 (fr) | 2008-04-01 |
| DE602006017982D1 (pt) | 2010-12-16 |
| IL186356A0 (en) | 2008-01-20 |
| MX2007012347A (es) | 2007-12-05 |
| BRPI0610454B8 (pt) | 2021-05-25 |
| ATE486612T1 (de) | 2010-11-15 |
| AU2006233812B2 (en) | 2011-07-28 |
| PT1865990E (pt) | 2011-02-07 |
| PL1865990T3 (pl) | 2011-04-29 |
| NO340565B1 (no) | 2017-05-15 |
| ES2354829T3 (es) | 2011-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110038T1 (hr) | Metoda liječenja dijabetesa tipa-2 | |
| ATE183926T1 (de) | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern | |
| KR960000219A (ko) | 당뇨병 합병증 치료용 조성물 | |
| BR9815378A (pt) | Sistema de fornecimento de droga transdérmico para agente analgésico antiinflamatório compreendendo sal de dietilamÈnio diclofenac e o método de fabricação do mesmo. | |
| BRPI0113670B8 (pt) | composição farmacêutica e método para tratar hipogonadismo | |
| GB2058563A (en) | Topical triethylenetetramine pharmaceutical compositions | |
| UA41989C2 (uk) | Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри | |
| JO3598B1 (ar) | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني | |
| RU2014125322A (ru) | Средство и способ трансдермальной доставки эстрогена | |
| JP2010530369A5 (pt) | ||
| WO2006110777B1 (en) | Method of treating or preventing bone deterioration or osteoporosis | |
| YU55899A (sh) | Cox-2 selektivni karprofen za lečenje bola i zapaljenja kod pasa | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
| DE69805983D1 (de) | Hustenhemmende, theobromine enthaltende zusammensetzungen | |
| WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
| WO2006000867B1 (en) | Compositions for topical treatment | |
| BRPI0703970A2 (pt) | tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona | |
| JP2008534644A5 (ja) | ２型糖尿病を治療または予防する組成物 | |
| KR860000867A (ko) | 급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물 | |
| BR0311371A (pt) | Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento | |
| AU687830B2 (en) | Compositions for deodorising animal excreta, and deodorising method therefor | |
| Evans et al. | Role of bacteria and inducible nitric oxide synthase activity in the systemic inflammatory microvascular response provoked by indomethacin in the rat | |
| IL126175A0 (en) | Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same | |
| AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta |